Boston, MA 03/13/2014 (wallstreetpr) – Foundation Medicine Inc (NASDAQ:FMI) is focused on changing how patients with cancer are treated. The company provides next-generation gene sequencing technology that delivers the kind of service that is value to patients, physicians and payers.
But before delving much on what the company is up to and how it is already working on its revenue, investors focused on clinical diagnostics and genetic medicine can learn something interesting about Foundation Medicine Inc (NASDAQ:FMI) as the company’s chief executive officer and president Michael Pellini speak at the 19th Annual Executive War College on April 29-30. The event will be in New Orleans at Sheraton Hotel.
Perhaps some of the most interesting things to capture are how the company went public just last year is different from others in the business of gene sequencing service and products provision. But before then, the company already has a lot that investors would be interested to find out.
Innovator On The Lead
Foundation Medicine Inc (NASDAQ:FMI) currently has two services namely FoundationOne and FoundationOneHeme. These technologies provide the referring physician with detailed information about genetic mutation discovered in the tissue of a patient and each service goes even further to guide in identifying the therapies associated with each gene mutation case.
The devices have retail prices of $5,800 for FoundationOne and $7,200 for FoundationOneHeme. The difference that these technologies offer is that they provide vital guidance to the physician based on the latest and more accepted clinical trials, therapeutics and developments in genomics.
Performance So Far
Foundation Medicine Inc (NASDAQ:FMI) was founded in 2009 and has been growing its revenue steadily. The company successfully underwent initial public offering in September 2013. During which $106 million was raised in the IPO. The company generated revenue of $29 million in 2013 and is looking to significant revenue growth this year, bearing in mind its attractive line of products. The company says that since introduction in 2012, more than 2,100 physicians have placed orders for FoundationOne.
